Sensitivity of *Trichomonas vaginalis* to metronidazole, tinidazole, and nifuratel *in vitro*

BENT KORNER AND HAAKON KAALUND JENSEN

From the Departments of Clinical Microbiology and Gynaecology,
Bispebjerg Hospital, Copenhagen, Denmark

Summary

Prompted by the sensitivity of trichomonads to metronidazole and nifuratel in clinical practice, a study was conducted in 1971-1972 of 63 consecutive strains of *Trichomonas vaginalis* isolated from women with clinically refractory vaginal discharge. Their susceptibility to metronidazole, tinidazole, and nifuratel was tested, using a serial tube dilution technique. The minimum concentrations which in 48 hrs caused immobilization and lysis of trichomonads cultured in Diamond's medium was assessed.

No differences in drug potency could be determined. The median trichomonistatic and trichomonicidal concentrations were 0.1 and 0.6 µg./ml. respectively when using an inoculum of 10,000 organisms per ml. An inoculum of 100,000 per ml. resulted in inhibitory concentrations of 1.0 and killing concentrations of 3.3 µg./ml. These levels are readily attained in blood and vaginal tissue after oral ingestion of the two imidazole derivatives.

Thus, metronidazole has maintained its efficacy since it was first introduced more than a decade ago. The few therapeutic failures with metronidazole and tinidazole are considered to have been caused by pharmacokinetic deficiencies in the patients, or by re-infection.

Introduction

In the chemotherapy of vaginal trichomoniasis, metronidazole has won world-wide acceptance since its introduction in 1958, and it has been the drug of choice in Denmark for more than a decade.

Recently, other antitrichomonal agents for oral use have been introduced in Denmark, namely

nifuratel (Polmisor®) in 1967 and tinidazole (Fasigyn®) in 1972. Both have shown promising results, though nifuratel requires to be given topically as well as by mouth.

The purpose of the present study was to compare the activity of these three compounds *in vitro* on clinical isolates of *Trichomonas vaginalis*.

Material and methods

Over a period of 20 months (1971/1972), 63 consecutive strains of *T. vaginalis* were examined. All strains were recovered from unselected women referred to two gynaecological clinics in Copenhagen City (at Bispebjerg Hospital and St. Joseph's Hospital) because of persistent vaginal discharge and other symptoms and signs of vaginitis; they were, however, not necessarily treatment-refractory cases. The diagnosis was confirmed at gynaecological examination.

The secretion was collected from the posterior fornix of the vagina by means of charcoal-impregnated cotton-wool swabs. They were stabbed into screw-capped tubes containing culture medium. The swabs were then removed again, and the tightly-closed tubes were taken to the laboratory within 2 hrs in a container kept at 35 to 40°C.

The tubes were incubated at 35°C. after a drop of the contents had been transferred to a slide and examined by phase-contrast microscopy.

Various culture media have been advocated for *T. vaginalis* (Taylor and Baker, 1968). Satisfactory results at the Danish State Serum Institute made us choose the medium of Diamond (1957) which supports many organisms per ml. (Capet, 1968; Howes, Lynch, and Kivlin, 1969; Christow, 1971; Nielsen, 1973).

To determine the minimal trichomonistatic and trichomonicidal concentrations (MIC and MCC) of metronidazole, tinidazole, and nifuratel, a standard 2-fold serial dilution test in Diamond's medium was employed, covering a range from 0.06 to 7.5 µg./ml.

The pre-warmed tubes containing the particular antitrichomonal agent and the control tube without agent were inoculated with a 48 hrs' culture. For the first successive nineteen strains 0.1 to 0.2 ml. were used, and for the next 44 strains 2.0 ml. To determine the inoculum size, 48 hrs' cultures of three different trichomonal strains were counted in Bürger-Türk's counting chamber. The counts ranged from 9.6 to 10.4×10^4 per ml.

After 48 hrs' incubation, the growth rate in the test tubes was estimated by counting the number of visible motile as well as non-motile trichomonads as observed in a standardized 4-ply criss-cross search of a wet mount (phase microscopy; $\times 640$). The results were read according to the system shown in Table I.

Results

Table II shows the typical overall growth sequence of a *T. vaginalis* culture under normal conditions and when an antitrichomonal drug is added in low and high concentrations.

The normal growth curve on the first incubation day consists of a lag phase followed by a logarithmic phase. The next 2 days the culture is full-grown and the conditions are optimal; all cells are highly motile and normal-looking without any appreciable admixture of abnormal or dead cells. From the fourth day onwards the growth curve declines; immobilization and death occur on the fifth day, and all cells are dead—as confirmed by subculture. No noticeable lysis takes place, however, until the following days. This sequence is qualitatively similar to that observed in Oxoid *T. vaginalis* medium No. 2 by Glahn (1973).

Under influence of low (inhibitory) concentrations of a chemotherapeutic agent, the cell motility is reduced during the initial growth phase. On the second day some of the cells die; the microscopic field presents a mixture of motile and nonmotile cells, some of them round, and a few ghost cells. Most of the less sensitive trichomonads survives and produce

delayed logarithmic growth density on the fifth day. Hereafter the growth curve slowly falls, ending in complete cell death and lysis around the tenth day. This retarded growth has also been described by Ødegaard (1962).

In presence of high (cidal) concentrations of an antiprotozoal agent, the growth curve is low and brief. The initial growth is accompanied by cell immobilization on the first day; the picture is characterized by a decreased number of organisms, mostly non-motile and lysed cells. Already on the second day almost all cells are dead; at this stage a few immobilized and partly lysed cells remain in the otherwise empty microscopic field. On the third day complete lysis of the culture occurs.

Daily subcultures from the sensitivity test tubes, read after 1 to 3 days' incubation, confirmed that the round immobile cells seen under the microscope were dead. When a mixture of motile and non-motile trichomonads are observed at lower drug concentrations, some survive. Accordingly, the drug concentration needed for complete immobilization almost equals the minimal trichomonocidal concentration—as noted by Ødegaard (1962).

The reproducibility attained was satisfactory. Some of the strains have been kept for up to 3 months in the laboratory by transfers every third day. In eight repeated sensitivity tests on different days the same activity was measured.

The results of the sensitivity studies are recorded in Table III. A total of 63 strains was examined. With the technique employed, no difference could

TABLE I Evaluation of growth of *T. vaginalis* and inhibition by drugs

Motile trichomonads at microscopy			Cell immobilization	Drug activity
Number	Count	Score		
Numerous	40	+++	None	Static level
Many	15-40	++	Partial	
Few	1-14	+	Substantial	
None	0	—	Complete	Cidal level

>40 per standardized search (see text) means >5 per microscopic field, which (according to Nielsen, 1969) corresponds to about 3×10^6 organisms per ml.

TABLE II Typical growth phases of *T. vaginalis* in Diamond's medium (inoculum about 100,000/ml.)

Day no.	Normal culture			Trichomonostatic culture		Trichomonocidal culture	
	Motile cells	Immobile cells	Growth phase	Motile cells	Immobile cells	Motile cells	Immobile cells
1	+++	—	Logarithmic	++	—	+	+
2	+++	—	Stationary	+	+	—	+
3	+++	—	Stationary	+	—	—	—
4	++	—	Decline	++	—	—	—
5	+	+++	Decline	+++	—	—	—
6	—	+++	Cessation	++	+	—	—
7	—	++		+	++	—	—
8	—	+		+	+	—	—
9	—	—		+	—	—	—
10	—	—		—	—	—	—

TABLE III *Sensitivity of T. vaginalis in vitro to three drugs (read after 48 hrs' incubation)*

Inoculum (<i>T. vaginalis</i> /ml.)	Drug	No. of strains	Static concentration (µg./ml.)		Cidal concentration (µg./ml.)	
			Range	Geometric mean	Range	Geometric mean
Small about 10,000	Metronidazole	19	0.06-1.00	0.14	0.25-1.50	0.59
	Tinidazole	10	0.12-0.25	0.13	0.50-1.50	0.71
	Nifuratel	19	0.06-0.25	0.09	0.12-1.50	0.52
Large about 100,000	Metronidazole	44	0.50-1.50	0.88	0.50-7.50	2.79
	Tinidazole	44	0.50-2.25	1.08	1.50-7.50	3.96
	Nifuratel	32	0.50-1.50	0.99	1.50-5.00	3.05

be detected between the potencies of the three drugs, at either static or cidal levels.

The static concentrations for the drugs ranged from 0.09 to 0.14 µg./ml. with the small inoculum (about 10^4), and from 0.99 to 1.08 with the large inoculum (about 10^5). The cidal concentrations ranged from 0.52 to 0.71 µg./ml. with the small inoculum, and from 2.79 to 3.96 with the large inoculum. Thus, a five to ten times higher concentration is necessary for inhibiting or killing a ten times larger inoculum. The ratio between the geometric means are slightly higher for MIC than for MCC.

When the tubes were examined after 24 hrs (instead of 48 hrs) the growth was often too sparse for estimation and comparison; this was also noted by Capet (1968).

We observed that the growth of *T. vaginalis* is influenced by the solvent dimethylformamide used for diluting nifuratel; this had not been considered by other investigators (Cavallo, 1963; Scuri and Failla, 1964). In serial dilution tests 0.25 per cent. formamide delays the multiplication, and a slightly higher concentration causes immobilization of part of the cell population. This antitrichomonal activity will certainly influence the results of tests employing higher contents of solvent.

Discussion

Some clinicians maintain that they have observed an increase in treatment failures with metronidazole, alleging that this may be due to the emergence of metronidazole-resistant strains of *T. vaginalis* in the community. We find no general support in the literature for this assumption. No overall decrease in the therapeutic efficacy of metronidazole has been observed (Keighley, 1971), and no resistant strains have been isolated in cases that did not respond to treatment (McFadzean, Pugh, Squires, and Whelan, 1969). The authors who suggest that resistant strains may have appeared (Arnold, 1966; Aure and Gjønness, 1969) did no microbiological tests.

Furthermore, attempts to induce resistance *in vitro* have failed (Ødegaard, 1962; Watt and Jennison, 1962; Nicol, McFadzean, and Squires, 1966a; Jennison, Stenton, and Watt, 1961; Squires and McFadzean, 1962) when not performed under extreme conditions.

The activity *in vitro* of the three antitrichomonal agents observed by other investigators are compared with our findings in Table IV. Metronidazole, the oldest of the drugs, has been carefully examined, but few data exist on the two newer drugs. Our results with the nitroimidazoles agree with those experiments in which many strains have been examined. On the other hand, our results with nifuratel differ from those reported by Scuri and Failla (1964) and Bénazet, Lacroix, Godard, Guillaume, and Leroy (1970). The former found MICs ten times smaller than we did, but the latter found MICs ten times greater than our mean. Neither study states the number of strains examined or the size of the inoculum so that the findings cannot be adequately evaluated. A recent study from England (Paredes and Hawkins, 1973) reported results similar to ours.

The correlation between the sensitivity of *T. vaginalis in vitro* and the clinical response to chemotherapy is probably determined by the levels attained in the tissues of the vaginal wall rather than by the levels in the discharge. Metronidazole is present in only very small amounts in vaginal secretions (Paredes and Hawkins, 1973). So far as we know assays of tissue concentrations have not been made, but some data on serum levels are available, although conflicting. Kane, McFadzean, Squires, King, and Nicol (1961) found peak serum levels of 3 to 6 µg./ml. 1 to 2 hrs after the injection of metronidazole 200 mg. three times daily for 7 days, whereas Csonka (1971) recorded levels varying between 0.5 and 46 µg./ml. (mean 16 µg./ml.). Nitroimidazole concentrations in human plasma during a course of 250 mg. metronidazole or tinidazole three times daily reached 7 to 13 µg./ml. (Taylor, Migliardi, and von Wittenau, 1969). After a single dose of 2 g. metronidazole achieved higher peak concentrations (mean 81 µg./ml.) than tinidazole (67 µg./ml.). However, the

TABLE IV Activity in vitro of metronidazole, tinidazole, and nifuratel against *T. vaginalis*

Authors	Date	No. of strains	Inoculum	Incubation period (days)	Inhibitory concentration ($\mu\text{g./ml.}$)		
					Metronidazole	Tinidazole	Nifuratel
Cosar and others	1959	1	1:400-000	1			
Jennison and others	1961	66		3	0.06-1.0		
Squires and McFadzean	1962	26		1	0.25-1.0		
Ødegaard	1962	43	1.4×10^6	2	0.08-2.5		
		43	1.4×10^6	4	0.08-0.3		
Cavallo	1963	3	2.5×10^4	1	>10		
Schröpl and Röckl	1963	105		2	0.06-8.0		
Scuri and Failla	1964		0.1 ml	2	2.5		0.25
Nielsen	1965	50	2.5×10^5	2	0.50-16		
McFadzean and others	1969	25		1	0.5-1.0		
Cantone and others	1969	8		3	0.3-6.0		
de Carneri and others	1969	2			0.23-6.0		
Prince and others	1969		0.2 ml	1	1.0		
Howes and others	1969		$4-10 \times 10^4$	1	2.5	1.25	
			$5-20 \times 10^5$	1	20	2.5	
Bénazet and others	1970			1	5		50
Csonka	1971	18			0.5-1.0		
Forsgren	1972	11	8×10^4	3	0.6		
Nielsen	1973	93*	2.5×10^5	2	0.25-16		
Paredes and Hawkins	1973	10	$\geq 6 \times 10^4$	2	0.8-2.3		0.5-1.5
Present study	1974	19	10^4	2	0.25-1.5	0.5-1.5	0.12-1.5
		44	10^5	2	0.5-7.5	1.5-7.7	1.5-5.0

MIC as determined by microscopical examination for absence of motile organisms

*includes 50 strains from 1965 study

longer serum half-life of tinidazole (12.5 hrs) than of metronidazole (7.3 hrs) led to equal areas-under-the-curve (Wood and Monro, 1975).

No data on the concentrations in humans are available for nifuratel. Rats fed 50 mg./kg. (Scuri and Failla, 1964) showed peak levels of 2 to 3 $\mu\text{g./ml.}$ in plasma after 30 min., 3 to 4 $\mu\text{g./ml.}$ in genital tissue after 2 hrs, and 30 to 50 $\mu\text{g./ml.}$ in urine. Since the normal single dose to man is 3 mg./kg., one would assume that active levels in tissues and secretions are not attained. The manufacturers also state that at lower doses the presence of nifuratel in plasma can not be ascertained by biological tests. Neither human nor animal urine reveal any antitrichomonal activity. Therefore, topical nifuratel application seems essential for its clinical effect.

The results of nifuratel therapy in experimental infections in animals are inconsistent. Scuri and Failla (1964) found that oral nifuratel was active against mouse trichomoniasis, whereas Bénazet and others (1970) claimed that nifuratel was inactive

against experimental subcutaneous abscesses in mice. This leaves the question open, but in view of the negligible tissue levels we would rather extrapolate from Bénazet's experiments to clinical conditions. The 50 per cent. curative dose (CD 50) of metronidazole against *T. vaginalis* and *T. foetus* abscesses in mice were 10 and 30 mg./kg./day (Bénazet and others, 1970). The corresponding activity of metronidazole and tinidazole against *T. foetus* peritonitis (Howes and others, 1969) and orchitis (Tsai and Price, 1973) in mice were about 50 and 10 mg./kg./day respectively. These experiments show that tinidazole is two to five times more active than metronidazole *in vivo*. Howes and others (1969) stated that tinidazole was more potent *in vitro* (Table IV), and exhibited a more rapid killing effect (it takes metronidazole 48 hrs to produce the same reduction rate as that produced by tinidazole in 8 hrs). This rather slow effect of metronidazole was also demonstrated by Ødegaard (1962); its maximum effect was first reached after more than 2 days for up to 4 days.

Conclusion

The examination of 63 strains of *T. vaginalis* isolated in the years 1971 to 1972 has shown that drug-resistant organisms were not present in an unselected group of women suffering from vaginitis. A few strains with the designation 'decreased sensitivity' to metronidazole were isolated from Danish patients in whom treatment had failed (Nielsen, 1973), but the overall susceptibility of these strains did not differ from the normal distribution found by us and by others in a series of patients with *T. vaginalis* (Ødegaard, 1962; Schröpl and Röckl, 1963). In view of these findings we are inclined to rule out *in vitro* resistance to metronidazole (or tinidazole) as the cause of the therapeutic failures which may be encountered. The causes are more likely to be re-infection, poor intestinal absorption (Kane and others, 1961), or destruction of the drugs (Nicol, Evans, McFadzean, and Squires, 1966b) by intestinal or vaginal bacteria and yeasts.

Our thanks are due to Mrs. Kirsten Larsen for her unflinching technical assistance.

References

- ARNOLD, M. (1966) *Ther. Umsch.*, **23**, 356
- AURE, J. C., and GJØNNÆSS, H. (1969) *Acta obstet. gynaec. scand.*, **48**, 440
- BÉNAZET, F., and GUILLAUME, L. (1972) *Lancet*, **1**, 597
- , LACROIX, L., GODARD, C., GUILLAUME, L., and LEROY, J.-P. (1970) *Scand. J. infect. Dis.*, **2**, 139
- BUSHBY, S. R. M., and COPP, F. C. (1955) *J. Pharm. Pharmacol.*, **7**, 112
- CANTONE, A., DE CARNERI, I., EMANUELI, A., GIRALDI, P. N., LOGEMAN, W., LONGO, R., MEINARDI, G., MONTI, G., NANNINI, G., TOSOLINI, G., and VITA, G. (1969) *G. Mal. infett.*, **21**, 954
- CAPET, R.-G. (1968) *Canad. J. publ. Hlth*, **59**, 201
- DE CARNERI, I., ACHILLI, G., MONTI, G., and TRANE, F. (1969) *Lancet*, **2**, 1308
- CAVALLO, G. (1963) 'Report on Thyodatil (nifuratel)'. Pisa
- CHRISTOW, C. P., (1971) *Zbl. Bakt. I. Abt. Orig.*, **217**, 540
- COSAR, C., JOULOU, L., and BÉNAZET, F. (1959) *Ann. Inst. Pasteur*, **96**, 238
- CSONKA, G. W. (1971) *Brit. J. vener. Dis.*, **47**, 456
- DIAMOND, L. S. (1957) *J. Parasit.*, **43**, 488
- FORSNGREN, A. (1972) *Brit. J. vener. Dis.*, **48**, 205
- GLAHN, B. E. (1973) *Ugeskr. Læg.*, **135**, 1293
- HOWES, H. L. Jr., LYNCH, J. E., and KIVLIN, J. L. (1969) *Antimicrob. Agents Chemother.*, **9**, 261
- JENEY, E., and ZSOLNAI, T. (1969) *Zbl. Bakt., I. Abt. Orig.*, **210**, 107
- JENNISON, R. F., STENTON, P., and WATT, L. (1961) *J. clin. Path.*, **14**, 431
- KANE, P. O., MCFADZEAN, J. A., SQUIRES, S., KING, A. J., and NICOL, C. S. (1961) *Brit. J. vener. Dis.*, **37**, 273
- KEIGHLEY, E. E. (1971) *Brit. med. J.*, **1**, 207
- MCFADZEAN, J. A., PUGH, I. M., SQUIRES, S. L., and WHELAN, J. P. F. (1969) *Brit. J. vener. Dis.*, **45**, 161
- NICOL, C. S., MCFADZEAN, J. A., and SQUIRES, S. L. (1966a) *Lancet*, **1**, 1100
- , EVANS, A. J., MCFADZEAN, J. A., and SQUIRES, S. L. (1966b) *Lancet*, **2**, 441
- NIELSEN, R. (1965) *Proc. fenn.-scand. Ass. Derm.*, **118**
- (1969) *Brit. J. vener. Dis.*, **45**, 328
- (1973) *Ugeskr. Læg.*, **135**, 921; *Brit. J. vener. Dis.*, **49**, 531
- ØDEGAARD, K. (1962) *Nord. Med.*, **68**, 1483
- PARADES, F. R., and HAWKINS, D. F. (1973) *J. Obstet. Gynaec. Brit. Cwlth*, **80**, 86
- PRINCE, H. N., GRUNBERG, E., TITSWORTH, E., and DELORENZO, W. F. (1969) *Appl. Microbiol.*, **18**, 728
- SCHRÖPL, F., and RÖCKL, H. (1963) *Z. Hyg. Infekt.-Kr.*, **149**, 126
- SCURI, R. (1971) *Scand. J. infect. Dis.*, **3**, 91
- and FAILLA, L. (1964) *Farmaco, Ed. sci.*, **19**, 301
- SQUIRES, S., and MCFADZEAN, J. A. (1962) *Brit. J. vener. Dis.*, **38**, 218
- TAYLOR, A. E. R., and BAKER, J. R. (1968) 'The Cultivation of Parasites *in vitro*', p. 98. Blackwell, Oxford
- TAYLOR, J. A., jr., MIGLIARDI, J. R., and VON WITTENAU, M. S. (1969) *Antimicrob. Agents Chemother.*, **9**, 267
- TSAT, Y. H., and PRICE, K. E. (1973) *Chemotherapy*, **18**, 348
- WATT, L., and JENNISON, R. F. (1962) *Brit. med. J.*, **1**, 276
- WOOD, B. A., and MONRO, A. M. (1975) *Brit. J. vener. Dis.*, **51**, 51